SALEKI-GERHARDT AZITA 4

4 · AbbVie Inc. · Filed Aug 14, 2025

Form 4

Period: 2025-08-12

EVP, CHIEF OPERATIONS OFFICER

Transactions

Exercise/Conversion
Common Stock, $0.01 par value
2025-08-12$54.86/sh+42,370$2,324,418→ 219,662 total
Sale
Common Stock, $0.01 par value
2025-08-12$198.42/sh−42,370$8,407,055→ 177,292 total
Exercise/Conversion
Option (Right to Buy)
2025-08-12$54.86/sh−42,370$2,324,418→ 0 total
Exercise: $54.86Exp: 2026-02-17→ Common Stock (42,370 underlying)

Holdings

Footnotes (4)

[F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.34 to $198.58, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]Balance in AbbVie Savings program as of August 1, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature.
[F3]The reporting person disclaims beneficial ownership of all securities held by her spouse.
[F4]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,124 on February 18, 2017, 14,123 on February 18, 2018, and 14,123 on February 18, 2019.

Documents

1 file